The FLT3 gene matters for acute myeloid leukemia (AML) survival because mutations in it, especially the FLT3-ITD type, drive leukemia cells to grow quickly and make relapse more likely after standard chemotherapy. The encouraging part is that FLT3 is now a treatment target. Adding an FLT3 inhibitor to chemotherapy, and moving eligible patients to a stem cell transplant, has narrowed much of the survival gap that FLT3-mutated AML once carried.
AML is an aggressive hematologic cancer in which immature myeloid cells multiply rapidly in the bone marrow. People often search for the acute myeloid leukemia FLT3 survival rate as if it were a single number. It isn’t. FLT3 status is one piece of the prognostic picture, and clinicians read acute myeloid leukemia survival rates alongside age, other genetic findings, fitness, and how the disease responds to treatment.
What Is FLT3 and Why Does It Matter in AML?
FLT3 (FMS-like tyrosine kinase 3) is a receptor on the surface of early blood-forming cells. When its normal signal, FLT3 ligand, binds to it, the receptor switches on growth and survival pathways inside the cell. In healthy marrow this signal is brief and tightly controlled.
A mutation can leave the receptor switched on all the time. The leukemia cell then receives a constant “grow and don’t die” message without needing the ligand. This is why FLT3-mutated AML often presents with a high white cell count and can come back quickly after treatment.
AML itself develops when immature cells called blasts crowd out normal blood production in the marrow. The result is anemia, infections from too few working white cells, and bruising or bleeding disorders from low platelets.
FLT3-ITD vs FLT3-TKD: Two Different Mutations
There are two main kinds of FLT3 mutation, and they do not carry the same weight. Your pathology report should say which one is present.
| Feature | FLT3-ITD | FLT3-TKD |
|---|---|---|
| What it is | Internal tandem duplication: a stretch of the gene is copied and repeated | Point mutation in the tyrosine kinase domain, most often at codon D835 |
| How common | Roughly a quarter to a third of adult AML | Less common, found in a smaller minority of cases |
| Effect on prognosis | Historically linked to higher relapse risk and shorter survival | Prognostic impact is less clear and generally milder |
| Targeted drugs | Midostaurin, quizartinib, gilteritinib | Midostaurin, gilteritinib (quizartinib does not act on TKD mutations) |
Older reports also mention the allelic ratio, which compares mutated to normal copies of the gene. A high ratio used to mean a worse outlook. Current European LeukemiaNet (ELN) guidance no longer uses the ratio for risk grouping, partly because FLT3 inhibitors have changed outcomes and the test was hard to standardize.
How FLT3 Fits Into AML Risk Assessment
FLT3 is never read in isolation. The same mutation can sit in very different overall risk groups depending on what else the leukemia carries.
- NPM1 co-mutation: NPM1-mutated AML is generally favorable. Under the current ELN classification, FLT3-ITD alongside NPM1 is grouped as intermediate risk.
- Adverse chromosome changes: Complex karyotype or other high-risk abnormalities push the overall picture into the adverse group regardless of FLT3.
- Age and fitness: Younger, fitter patients can receive intensive chemotherapy and transplant, which strongly affects survival.
- Response to treatment: Reaching complete remission and clearing measurable residual disease (MRD) are among the strongest predictors of long-term outcome.
In my practice, I tell families that the FLT3 result tells us which drugs to add and how urgently to plan a transplant. It does not, by itself, decide how the story ends.
Testing for FLT3 at Diagnosis
Diagnosis starts with a blood count, a peripheral blood smear, and a bone marrow aspiration to count blasts and study their features. The marrow sample, drawn from the spongy tissue described in our overview of bone marrow composition and function, also goes for flow cytometry, chromosome analysis, and molecular testing.
FLT3 testing is done by a rapid PCR-based assay, often with results in a few days. Speed matters because an FLT3 inhibitor should be added early in induction therapy. Many centers also run a broader next-generation sequencing panel that checks NPM1, CEBPA, TP53, and other genes at the same time.
FLT3 status can change over time. A mutation may appear or disappear at relapse, so the test is repeated whenever AML comes back.
Treatment for FLT3-Mutated AML
For fit adults, treatment follows the standard phases of AML care, with FLT3-targeted drugs layered on top.
Induction and Consolidation
Induction aims for complete remission, usually with the “7+3” regimen: seven days of cytarabine and three days of an anthracycline. For FLT3-mutated disease, midostaurin (for ITD or TKD) or quizartinib (for ITD) is added. Consolidation cycles then aim to destroy leukemia cells that remain below the level visible on a microscope.
Stem Cell Transplant
Because relapse risk is the main problem in FLT3-ITD AML, many patients are referred for allogeneic hematopoietic stem cell transplant in first remission. The donor immune system helps control residual leukemia, an effect called graft-versus-leukemia.
Maintenance and Relapse
After transplant, some patients take an FLT3 inhibitor as maintenance to lower relapse risk. For relapsed or refractory FLT3-mutated AML, gilteritinib taken as a single oral drug is a standard option. Older or less fit patients may receive lower-intensity treatment, such as azacitidine with venetoclax, sometimes combined with an FLT3 inhibitor in specialist settings.
Side Effects and Monitoring
FLT3 inhibitors are not free of problems. Common issues include low blood counts, nausea, and liver enzyme changes. Some agents can prolong the QT interval on the ECG, so heart tracings and electrolyte checks are routine. Gilteritinib can rarely cause differentiation syndrome, with fever, breathlessness, and fluid build-up, which needs prompt treatment.
During and after therapy, teams track blood counts, marrow response, and MRD. Rising MRD can flag an impending relapse early enough to change the plan.
Key Takeaways
- FLT3 mutations, particularly FLT3-ITD, are among the most common genetic changes in AML and historically worsened survival.
- FLT3-ITD and FLT3-TKD behave differently, and not every FLT3 inhibitor targets both.
- Rapid FLT3 testing at diagnosis lets doctors add an inhibitor during induction.
- Overall risk depends on co-mutations such as NPM1, chromosome findings, age, fitness, and MRD response.
- Targeted drugs and transplant have substantially improved the outlook compared with chemotherapy alone.
Frequently Asked Questions
Does an FLT3 mutation mean my AML cannot be cured?
No. FLT3-mutated AML is treated with curative intent in fit patients. Chemotherapy plus an FLT3 inhibitor, followed by transplant when appropriate, leads to long-term remission for many people. Your team can explain where your case sits based on your full genetic profile.
Is FLT3 AML inherited?
FLT3 mutations in AML are acquired in the leukemia cells during life. They are not passed from parents and are not a reason for family members to be tested.
Why does my doctor want a transplant if I am already in remission?
Remission means leukemia is no longer detectable by standard tests, but FLT3-ITD disease has a higher chance of returning. A transplant in first remission aims to eliminate remaining leukemia cells before they regrow. The decision weighs your relapse risk against transplant risks and donor availability.
How long do people stay on FLT3 inhibitors?
It depends on the drug and the stage of treatment. Midostaurin or quizartinib is given with induction and consolidation, and maintenance may continue for months afterward. Gilteritinib for relapsed disease is usually continued as long as it is working and tolerated.
